ITMI20091007A1 - Metodo di monitoraggio e trattamento - Google Patents

Metodo di monitoraggio e trattamento Download PDF

Info

Publication number
ITMI20091007A1
ITMI20091007A1 ITMI20091007A ITMI20091007A1 IT MI20091007 A1 ITMI20091007 A1 IT MI20091007A1 IT MI20091007 A ITMI20091007 A IT MI20091007A IT MI20091007 A1 ITMI20091007 A1 IT MI20091007A1
Authority
IT
Italy
Prior art keywords
patient
cells
references
leukemia
chromosome
Prior art date
Application number
Other languages
English (en)
Italian (it)
Inventor
Giovanni Porta
Original Assignee
Giovanni Porta
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Giovanni Porta filed Critical Giovanni Porta
Priority to ITMI20091007 priority Critical patent/ITMI20091007A1/it
Priority to PCT/EP2010/003747 priority patent/WO2010142467A1/fr
Publication of ITMI20091007A1 publication Critical patent/ITMI20091007A1/it

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • External Artificial Organs (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ITMI20091007 2009-06-09 2009-06-09 Metodo di monitoraggio e trattamento ITMI20091007A1 (it)

Priority Applications (2)

Application Number Priority Date Filing Date Title
ITMI20091007 ITMI20091007A1 (it) 2009-06-09 2009-06-09 Metodo di monitoraggio e trattamento
PCT/EP2010/003747 WO2010142467A1 (fr) 2009-06-09 2010-06-08 Procédé de surveillance d'une maladie provoquée par une translocation génomique

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITMI20091007 ITMI20091007A1 (it) 2009-06-09 2009-06-09 Metodo di monitoraggio e trattamento

Publications (1)

Publication Number Publication Date
ITMI20091007A1 true ITMI20091007A1 (it) 2010-12-10

Family

ID=42537672

Family Applications (1)

Application Number Title Priority Date Filing Date
ITMI20091007 ITMI20091007A1 (it) 2009-06-09 2009-06-09 Metodo di monitoraggio e trattamento

Country Status (2)

Country Link
IT (1) ITMI20091007A1 (fr)
WO (1) WO2010142467A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130210645A1 (en) 2010-02-18 2013-08-15 The Johns Hopkins University Personalized tumor biomarkers

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101918831B (zh) 2007-11-08 2014-10-15 华盛顿大学 以dna微阵列为基础的平衡易位断点的鉴定和定位

Also Published As

Publication number Publication date
WO2010142467A1 (fr) 2010-12-16

Similar Documents

Publication Publication Date Title
US20200024669A1 (en) Genomic stability profiling
Karrman et al. Pediatric T‐cell acute lymphoblastic leukemia
Ye et al. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer
US7622253B2 (en) Classification of patients having diffuse large b-cell lymphoma based upon gene expression
Roshal et al. Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: implications for minimal residual disease detection
Maeda et al. Expression of SIP1 in oral squamous cell carcinomas: implications for E-cadherin expression and tumor progression
Kees et al. Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG)
Weinberg et al. Clinical and molecular predictors of disease severity and survival in chronic lymphocytic leukemia
CN106662543A (zh) 肺癌患者中的非侵入性基因突变检测
Johnson et al. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow
Kluckova et al. B-cell receptor signaling induced metabolic alterations in chronic lymphocytic leukemia can be partially bypassed by TP53 abnormalities
Fong et al. An investigation of the differential expression of Her2/neu gene expression in normal oral mucosa, epithelial dysplasia, and oral squamous cell carcinoma in Taiwan
Kalashyan et al. Patient-derived enteroids provide a platform for the development of therapeutic approaches in microvillus inclusion disease
Bendardaf et al. CD44 variant 6 expression predicts response to treatment in advanced colorectal cancer
El Masri et al. A postzygotic GNA13 variant upregulates the RHOA/ROCK pathway and alters melanocyte function in a mosaic skin hypopigmentation syndrome
JP6273552B2 (ja) アザシチジン耐性を診断する検査
Funato et al. Assessment of drug resistance in acute myeloid leukemia
Tsunoda et al. Characteristic Genes in Luminal Subtype Breast Tumors with CD44+ CD24–/Low Gene Expression Signature
US20200377958A1 (en) Biomarkers and methods for treatment with nae inhibitors
WO2007099852A1 (fr) Procédé destiné à tester la sensibilité d'un cancer solide contre un inhibiteur de tyrosine kinase et nécessaire de test correspondant
WO2010142467A1 (fr) Procédé de surveillance d'une maladie provoquée par une translocation génomique
Mithraprabhu et al. Liquid biopsy in multiple myeloma
Wehner et al. Calcium release from sarcoplasmic reticulum is facilitated in human myotubes derived from carriers of the ryanodine receptor type 1 mutations Ile2182Phe and Gly2375Ala
Kadlcikova et al. Different chromosome damage in lymphocytes of newly diagnosed gastrointestinal and breast cancer patients.
US20090098537A1 (en) Biomarker for Sensitivity to mTOR Inhibitor Therapy in Kidney Cancer